Tag: officers

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Broadmark Realty Capital Inc. (“Broadmark” or “the Company”) (NYSE: BRMK), Ready Capital Corporation ("Ready Capital") (NYSE: RC), and certain officers.

NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against DoubleVerify Holdings, Inc. (“DoubleVerify” or “the Company”) (NYSE: DV) and certain of its officers.

Washington, DC, July 19, 2025 (GLOBE NEWSWIRE) --

Link to ThinkCareBelieve's Article:  https://thinkcarebelieve.blog/2025/07/19/week-26-in-americas-rebirth/

NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

CHARLOTTE, N.C. and STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- HCM II Acquisition Corp., (Nasdaq: HOND), (“HCM II”), a special-purpose acquisition company and Terrestrial Energy Inc., (“Terrestrial Energy”), a developer of small modular nuclear plants using advanced reactor technology, today announced the filing of the draft registration statement on Form S-4 with the U.S. Securities and Exchange Commission (“SEC”).

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group," “Aptorum” or the "Company"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs in oncology  and infectious diseases, and DiamiR Biosciences (“DiamiR”), a developer of proprietary innovative blood-based tests for brain health and other diseases with a CLIA licensed, CAP accredited clinical laboratory in New Haven, CT, today announced that they have entered into a definitive agreement for an all-stock merger transaction, in which DiamiR Biosciences will retain its name and become a wholly-owned subsidiary of Aptorum Group upon consummation of the merger.The combined company expects to remain listed on the Nasdaq Stock Market following the closing of the merger.